Loading…

Design and Characterization of Polyvinyl Alcohol/Kappa‐Carrageenan Pickering Emulsion Biocomposite Films for Potential Wound Care Applications

ABSTRACT This study aimed to develop polyvinyl alcohol (PVA) and kappa‐carrageenan (κCA) biocomposite films using a Pickering emulsion technique for wound care applications. Juniper essential oil and modified sepiolite were incorporated to enhance functionality, with films prepared via solvent casti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical materials research. Part A 2025-01, Vol.113 (1), p.e37850-n/a
Main Authors: Yeşilyurt, Ayşenur, Mayakrishnan, Gopiraman, Parın, Uğur, Kim, Ick Soo, Parın, Fatma Nur, Ullah, Azeem
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT This study aimed to develop polyvinyl alcohol (PVA) and kappa‐carrageenan (κCA) biocomposite films using a Pickering emulsion technique for wound care applications. Juniper essential oil and modified sepiolite were incorporated to enhance functionality, with films prepared via solvent casting and characterized for structural, thermal, and mechanical properties. The PCOS‐2 film exhibited the highest mechanical performance, with Young's modulus of 6.25 ± 1.3 MPa, tensile strength of 5.65 ± 1.7 MPa, and elongation at break of 608.96% ± 72.8%. Antibacterial assays showed inhibition zones of 9 and 10 mm against Staphylococcus aureus and Escherichia coli, respectively, for the PCOS‐2 film, while antioxidant activity reached 63% DPPH radical scavenging after 12 h. Additionally, porosity and hydrophilicity were enhanced, as indicated by contact angles of 55° for the control film and 71.2° for PCOS‐2. These results underscore the potential of PVA/κCA biocomposite films as sustainable and bioactive wound dressings, combining mechanical resilience, bioactivity, and environmental compatibility, with future efforts focused on optimizing antibacterial efficacy against gram‐negative bacteria and clinical validation.
ISSN:1549-3296
1552-4965
1552-4965
DOI:10.1002/jbm.a.37850